Cargando…
Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer
Pancreatic cancer is projected to be the second leading cause of cancer-related death by 2030 in the US. The benefits of the most common systemic therapy for various pancreatic cancers have been masked by high drug toxicities, adverse reactions, and resistance. The use of nanocarriers such as liposo...
Autores principales: | Ndemazie, Nkafu Bechem, Bulusu, Raviteja, Zhu, Xue You, Frimpong, Esther Kesewaah, Inkoom, Andriana, Okoro, Joy, Ebesoh, Dexter, Rogers, Sherise, Han, Bo, Agyare, Edward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002367/ https://www.ncbi.nlm.nih.gov/pubmed/36901721 http://dx.doi.org/10.3390/ijms24054288 |
Ejemplares similares
-
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer
por: Ndemazie, Nkafu Bechem, et al.
Publicado: (2022) -
Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer
por: Inkoom, Andriana, et al.
Publicado: (2023) -
Multi-disciplinary Approach for Drug and Gene Delivery Systems to the Brain
por: Ndemazie, Nkafu Bechem, et al.
Publicado: (2021) -
Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models
por: Inkoom, Andriana, et al.
Publicado: (2020) -
Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon
por: Dimala, Christian Akem, et al.
Publicado: (2017)